SAMIL

Serial Number 97558803
Registration 7603272
700

Registration Progress

Application Filed
Aug 22, 2022
Under Examination
Approved for Publication
Oct 15, 2024
Published for Opposition
Oct 15, 2024
Registered
Dec 17, 2024

Trademark Image

SAMIL

Basic Information

Serial Number
97558803
Registration Number
7603272
Filing Date
August 22, 2022
Registration Date
December 17, 2024
Published for Opposition
October 15, 2024
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Dec 17, 2024
Registration
Registered
Classes
005

Rights Holder

Samil Pharmaceutical Co., Ltd.

03
Address
155 Hyoryeong-ro, Seocho-gu
Seoul 06666
KR

Ownership History

Samil Pharmaceutical Co., Ltd.

Original Applicant
03
Seoul KR

Samil Pharmaceutical Co., Ltd.

Owner at Publication
03
Seoul KR

Samil Pharmaceutical Co., Ltd.

Original Registrant
03
Seoul KR

Legal Representation

Attorney
Arno Naeckel

Application History

38 events
Date Code Type Description Documents
Dec 17, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Dec 17, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Nov 24, 2024 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Nov 24, 2024 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Nov 24, 2024 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Oct 15, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 15, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 25, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 9, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 8, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 8, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 8, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 23, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 23, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 23, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 18, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 18, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 17, 2024 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Apr 16, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 16, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 16, 2024 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Apr 16, 2024 GNSL F LETTER OF SUSPENSION E-MAILED Loading...
Apr 16, 2024 CNSL R SUSPENSION LETTER WRITTEN Loading...
Apr 15, 2024 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Jan 22, 2024 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Jan 22, 2024 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Jan 22, 2024 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Jan 17, 2024 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Jun 15, 2023 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Jun 15, 2023 GNSL F LETTER OF SUSPENSION E-MAILED Loading...
Jun 15, 2023 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jun 8, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 7, 2022 AMPX O PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Loading...
Oct 7, 2022 ALIE A ASSIGNED TO LIE Loading...
Sep 13, 2022 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Sep 10, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 29, 2022 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Aug 25, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the prevention and treatment of ophthalmic diseases; pharmaceutical preparations for the treatment of ophthalmic conditions; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, crohn's disease, irritable bowel syndrome; pharmaceutical preparations for the treatment of pain

Additional Information

Design Mark
The mark consists of the underlined word "SAMIL" in cursive writing.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005